Universitaetsklinikum Regensburg AöR
- Address
- lock Available on a paid plan
Ophthalmology and Vision Research
At Universitaetsklinikum Regensburg AöR, clinical trials in Eye Diseases focus on urgent vision-threatening conditions such as acute central retinal artery occlusion. The research aims to improve recovery of sight and to test more effective approaches for restoring visual function after sudden retinal injury.
- Recovery of vision in acute retinal artery occlusion
- Functional improvement measured through visual acuity outcomes
- Testing new strategies to protect or restore eyesight
These studies reflect a strong interest in faster diagnosis and better treatment options for patients facing sudden loss of vision.
Oncology and Immunotherapy
The site conducts a broad range of trials in Neoplasms, including melanoma, solid tumors, non-small cell lung cancer, gastroesophageal adenocarcinoma, and head and neck cancers. Many of these studies evaluate immunotherapy combinations and other targeted treatments to improve tumor control, delay recurrence, and extend survival.
- Melanoma and metastatic melanoma
- Locally advanced or metastatic non-small cell lung cancer
- Head and neck squamous cell carcinoma
- Advanced gastroesophageal adenocarcinoma
The oncology portfolio includes both treatment innovation and post-surgery recurrence prevention, showing a clear focus on more personalized cancer care.
Hematology and Pediatric Blood Cancers
Research in immune system diseases and neoplasms includes trials for acute myeloid leukemia, myelodysplastic syndromes, classical Hodgkin lymphoma, and aggressive B-cell lymphoma in children and adolescents. These studies are designed to refine treatment effectiveness, preserve event-free survival, and support immune recovery while reducing treatment burden where possible.
- Acute myeloid leukemia and related myelodysplastic syndromes
- Classical Hodgkin lymphoma
- Pediatric mature aggressive B-cell lymphoma and leukemia
- Evaluating optimized chemotherapy and immunotherapy combinations
This area highlights the clinic’s role in advancing both adult and pediatric blood cancer research.
Cardiovascular and Acute Care Studies
Trials in Cardiovascular Diseases address high-risk conditions such as acute myocardial infarction. The main purpose is to improve early treatment and reduce the risk of recurrent cardiac events through better use of anti-thrombotic and emergency therapies.
- Acute myocardial infarction
- Preventing repeat cardiac events
- Evaluating rapid self-administered treatment approaches
These studies emphasize timely intervention in life-threatening cardiovascular emergencies.
Transplant Medicine and Immune Rejection
Research involving immune system processes includes studies in kidney transplant recipients focused on prophylaxis of transplant rejection. The goal is to compare treatment options that may improve drug exposure and support long-term graft protection after transplantation.
- Kidney transplant recipients
- Prevention of transplant rejection
- Comparing oral immunosuppressive treatment performance
These trials contribute to safer and more reliable post-transplant care.
Inflammation and Skin Disease Research
The site also studies skin and connective tissue diseases, especially hidradenitis suppurativa. This work evaluates whether newer anti-inflammatory treatments can better control symptoms in people with moderate to severe disease who have not responded adequately to prior therapy.
- Hidradenitis suppurativa
- Chronic inflammatory skin disease management
- Assessing treatment effectiveness and tolerability
Overall, the research aims to improve symptom control and quality of life for patients with difficult-to-treat inflammatory skin conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 21 therapeutic areas and 15 of 408 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 373 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 78 by active trials.
- 1AstraZeneca AB11active
lock +77 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB22trials
lock +49 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Regensburg AöR
lock Showing 1 of 272 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A DOSE-BLINDED EXTENSION STUDY TO EVALUATE THE LONG-TERM EFFICACY, SAFETY, AND TOLERABILITY OF UCB0599 IN STUDY PARTICIPANTS WITH PARKINSON’S DISEASE | UCB Biopharma | Phase II | Not Recruiting | Dec 2022 | Mar 2025 |
IMP list
lock Showing 1 of 408 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cisplatin | 25 | Unknown | 2015-06-02 | 2026-01-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
